aadi bioscience inc. (aadi), is a rapidly growing biopharmaceutical company focused on the development and commercialization of precision medicines targeted to rare genomic alteration-driven cancers. aadi’s lead asset, fyarrotm (sirolimus albumin-bound nanoparticles for injectable suspension), is an mtor inhibitor targeting cancers driven by genetic alterations in mtor pathway genes. supported by leading healthcare investors, aadi is currently preparing for launch of fyarro in advanced malignant pecoma, a rare type of sarcoma with no previously approved therapies. aadi’s world class leadership team is comprised of industry veterans from top biotech companies who have proven track records of bringing blockbuster products to market. a science-first mindset and entrepreneurial spirit is in our genes. aadi’s vision to become a leading precision oncology company is further supported by ongoing work in tumor-agnostic biomarker-driven populations (e.g., pan tumor tsc1/2 alterations) and n
Company profile
Ticker
AADI
Exchange
Website
CEO
Joseph H. Gardner
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Aerpio Pharmaceuticals, Inc., ZETA ACQUISITION CORP II
SEC CIK
AADI stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
13 Mar 24
8-K
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
13 Mar 24
S-8
Registration of securities for employees
12 Feb 24
S-3
Shelf registration
12 Feb 24
8-K
80 patients now enrolled in PRECISION1 supporting two-thirds interim analysis expected in 3Q 2024
14 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K/A
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
8 Nov 23
8-K
Results of Operations and Financial Condition
8 Nov 23
8-K
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
2 Oct 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
Transcripts
AADI
Earnings call transcript
2023 Q4
13 Mar 24
AADI
Earnings call transcript
2023 Q3
8 Nov 23
AADI
Earnings call transcript
2023 Q2
9 Aug 23
AADI
Earnings call transcript
2023 Q1
10 May 23
AADI
Earnings call transcript
2022 Q4
28 Mar 23
AADI
Earnings call transcript
2022 Q3
9 Nov 22
AADI
Earnings call transcript
2022 Q2
10 Aug 22
AADI
Earnings call transcript
2022 Q1
12 May 22
AADI
Earnings call transcript
2020 Q3
10 Nov 20
AADI
Earnings call transcript
2020 Q2
12 Aug 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 68.80 mm | 68.80 mm | 68.80 mm | 68.80 mm | 68.80 mm | 68.80 mm |
Cash burn (monthly) | (no burn) | 5.50 mm | 5.95 mm | 5.81 mm | 3.98 mm | 5.11 mm |
Cash used (since last report) | n/a | 32.88 mm | 35.57 mm | 34.72 mm | 23.81 mm | 30.55 mm |
Cash remaining | n/a | 35.92 mm | 33.24 mm | 34.09 mm | 44.99 mm | 38.25 mm |
Runway (months of cash) | n/a | 6.5 | 5.6 | 5.9 | 11.3 | 7.5 |
Institutional ownership, Q3 2023
65.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 74 |
Opened positions | 12 |
Closed positions | 6 |
Increased positions | 25 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 72.43 bn |
Total shares | 16.13 mm |
Total puts | 800.00 |
Total calls | 10.00 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Avoro Capital Advisors | 2.85 mm | $13.79 bn |
Acuta Capital Partners | 1.85 mm | $8.95 bn |
Satter Management | 1.63 mm | $7.89 bn |
BLK Blackrock | 1.01 mm | $4.87 bn |
Baker Bros. Advisors | 989.93 k | $4.79 bn |
Biotechnology Value Fund L P | 899.39 k | $21.72 mm |
JHG Janus Henderson | 780.37 k | $3.78 bn |
Vanguard | 771.38 k | $3.73 bn |
Decheng Capital Management III | 526.33 k | $2.55 bn |
Vivo Capital | 509.57 k | $6.46 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Neil Desai | Common Stock | Sell | Dispose S | Yes | Yes | 2.0994 | 14,964 | 31.42 k | 1,411,543 |
1 Mar 24 | Neil Desai | Common Stock | Sell | Dispose S | Yes | Yes | 1.9687 | 27,036 | 53.23 k | 1,426,507 |
1 Mar 24 | Lorettta M Itri | RSU Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 30,000 |
1 Mar 24 | Lorettta M Itri | Stock option Common Stock | Grant | Acquire A | No | No | 1.92 | 60,000 | 115.20 k | 60,000 |
1 Mar 24 | Lorettta M Itri | Stock option Common Stock | Grant | Acquire A | No | No | 1.92 | 76,813 | 147.48 k | 76,813 |
1 Mar 24 | David James Lennon | RSU Common Stock | Grant | Acquire A | No | No | 0 | 65,000 | 0.00 | 65,000 |
1 Mar 24 | David James Lennon | Stock Option Common Stock | Grant | Acquire A | No | No | 1.92 | 130,000 | 249.60 k | 130,000 |
1 Mar 24 | David James Lennon | Stock option Common Stock | Grant | Acquire A | No | No | 1.92 | 30,768 | 59.07 k | 30,768 |
1 Mar 24 | Scott M. Giacobello | RSU Common Stock | Grant | Acquire A | No | No | 0 | 27,000 | 0.00 | 27,000 |
1 Mar 24 | Scott M. Giacobello | Stock Option Common Stock | Grant | Acquire A | No | No | 1.92 | 55,000 | 105.60 k | 55,000 |
News
Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With nab-Sirolimus At Society Of Gynecologic Oncology
18 Mar 24
Aadi Bioscience Q4 GAAP EPS $(0.60) Beats $(0.65) Estimate, Sales $6.33M Beat $6.29M Estimate
13 Mar 24
Earnings Scheduled For March 13, 2024
13 Mar 24
Aadi Bioscience Earnings Preview
12 Mar 24
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
4 Mar 24
Press releases
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
17 Mar 24
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
13 Mar 24
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
5 Mar 24
Thinking about buying stock in Aadi Bioscience, Bitdeer Technologies, Aquestive Therapeutics, 89bio, or Energem?
4 Mar 24
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
1 Mar 24